News | January 01, 2026
HUTCHMED’s Fanregratinib gains priority review in China for aggressive liver cancer
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The funding will accelerate Sinopia’s data-driven drug discovery efforts
Applications include detailed scientific rationale and supporting clinical evidence
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
The study met its primary endpoint with flying colors
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Subscribe To Our Newsletter & Stay Updated
